Click Here to return To Results

 

Subcutaneous Apomorphine in the Treatment of Parkinson's Disease JNNP 53:96-101, Frankel,J.P.,et al, 1990 See this aricle in Pubmed Article Abstract Apomorphine a dopamine receptor agonist was given subcutaneously to 57 levodopa treated parkinsonian patients with refractory off-period disabilities for a medial period of 16 months.In 30 given intermittent suprathreshold injections the mean number of hours spent in a disabling off state fell from 6-9 to 2-9.Similar benefit was observed in 21 patients receiving continuous infusions with additional boluses on demand by mini- pump(mean reduction of hours off from 9-9 to 4-5).Twelve patients have been treated for over two years without tachyphylaxis or loss of response. The incidence of neuropsychiatric side-effects has been low(7%).Six patients failed to show a sustained worthwhile response;severe disabilities during"on"periods being the major problem.Subcutaneous apomorphine is proposed as an effective treatment for patients with incapacitating"off"period disabilities refractory to oral medication and should be considered before experimental implantation procedures.

Related Tags

(click to filter results - removes previous filter) apomorphine dopamine agonist Parkinson disease Parkinson disease,on-off phenomena in Parkinson disease,treatment of treatment of neurologic disorder

Click Here to return To Results